摘要
目的建立前列腺癌的焦磷酸测序技术为基础DNA甲基化的定量分析方法,并比较良性前列腺增生和前列腺癌组织中GSTP1、CDH1和p16基因DNA甲基化差异,为临床早期诊断前列腺癌奠定基础。方法取前列腺癌组织和良性前列腺增生组织石蜡切片标本,使用焦磷酸测序仪定量检测GSTP1、CDH1和p16基因启动子甲基化状态。结果前列腺癌组织与良性前列腺增生组织比较GSTP1基因超甲基化率为56%(14/25),CDH1基因超甲基化率为32%(8/25),p16基因超甲基化率为20%(5/25)。其中GSTP1、CDH1基因有统计学差异(P<0.05)。结论 GSTP1、CDH1基因在前列腺癌组织中甲基化程度可作为前列腺癌早期诊断的标志物,焦磷酸测序实时定量检测DNA甲基化技术是快速、灵敏、高通量的检测方法。
Objective To establish and evaluate a quantitative method to analyzing genomic DNA methylation level for early clinical diagnosis of prostate cancer, and to compare GSTP1, CDH1 and p16 genes methylation levels between benign prostatic hyperplasia and prostate cancer. Methods We obtained the tissue specimens from benign prostatic hyperplasia and prostate cancer, and examined the level of gene promoter methylation of GSTP1, CDH1 and p16 by pyrosequencing. Results Compared with benign prostatic hyper- plasia, the GSTP, CDH1, p16 gene hypemethylation rate was respectively 56% （ 14/25 ） , 32% （ 8/25 ） and 20% （5/25） in prostate cancer. The differences in GSTP and CDH1 were statistically significant （ P 〈 0.05 ）. Conclusion The methylation levels of GSTP1 and CDH1 genes in prostate cancer tissues can be used as good markers for early diagnosis of prostate cancer. Pyrosequencing real-time quantitative detection is a quick, sensitive and high throughput detection method.
出处
《临床军医杂志》
CAS
2013年第6期577-579,591,共4页
Clinical Journal of Medical Officers
